Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PKSD | ISIN: NO0010851603 | Ticker-Symbol: 7UM
Düsseldorf
21.11.24
08:12 Uhr
0,179 Euro
+0,010
+6,16 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ULTIMOVACS ASA Chart 1 Jahr
5-Tage-Chart
ULTIMOVACS ASA 5-Tage-Chart
RealtimeGeldBriefZeit
0,1830,21623:01

Aktuelle News zur ULTIMOVACS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
ULTIMOVACS Aktie jetzt für 0€ handeln
06.11.Ultimovacs ASA Reports Third Quarter 2024 Financial Results and Provides General Business Update7
25.10.Ultimovacs ASA: Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv1
11.09.Ultimovacs ASA: Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Trial Investigating UV1 Combined with Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer1
07.08.Ultimovacs ASA: Ultimovacs Announces Notice of Resignation from Deputy Board Member1
06.08.Ultimovacs cancer vaccine goes 0 for 3, shuffling into last chance saloon with latest failure4
05.08.Ultimovacs ASA: Ultimovacs Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with Pembrolizumab in Patients with Metastatic or Recurrent Head and Neck Cancer3
01.08.Ultimovacs ASA: Ultimovacs Announces Poster Presentation of NIPU Phase II Trial Update at Upcoming ESMO Congress 20241
11.06.Ultimovacs ASA: Ultimovacs provides update from Phase I study in malignant melanoma: Continued strong overall survival in patients treated with UV1 cancer vaccine and pembrolizumab4
01.06.Ultimovacs ASA: Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology Annual Meeting1
18.04.Ultimovacs - Steadfast commitment to UV1 progression277Despite the recent setback with the INITIUM trial (first-line treatment of patients with unresectable or metastatic malignant melanoma), Ultimovacs has reinstated its commitment to press on with its...
► Artikel lesen
07.03.Ultimovacs - UV1 hits transitory roadblock with INITIUM top-line770Ultimovacs has announced top-line results for the Phase II INITIUM trial evaluating its cancer vaccine for the treatment of malignant melanoma. While UV1 maintained its desirable safety and tolerability...
► Artikel lesen
04.03.Ultimovacs - Peer-reviewed publication reiterates UV1's potential270Ultimovacs' results from the Phase II NIPU trial for its universal, off-the-shelf cancer vaccine UV1 in second-line metastatic pleural mesothelioma (MPM) have been published in the European Journal...
► Artikel lesen
20.02.Ultimovacs - Another ODD boosts the off-the-shelf, universal UV1358Ultimovacs has been granted Orphan Drug designation (ODD) from the European Medicines Agency (EMA) for UV1 in mesothelioma, marking another step forward for the clinical development of its lead universal...
► Artikel lesen
16.02.Ultimovacs - Universal approach with critical readouts in March297Ultimovacs recapped an active FY23 period for its universal cancer vaccine, UV1, including the reported benefit in overall survival and desirable safety profile from the NIPU trial in malignant pleural...
► Artikel lesen
06.02.Ultimovacs - FDA Fast Track boosts confidence in UV1365Ultimovacs has received FDA Fast Track designation for its lead cancer vaccine, UV1, as a potential treatment for mesothelioma and builds on the Orphan Drug designation (ODD) already received in this...
► Artikel lesen
17.01.Ultimovacs - INITIUM: March 2024 top-line timeline confirmed357Ultimovacs has confirmed that top-line results for the Phase II INITIUM trial (investigating lead candidate UV1 in combination with ipilimumab and nivolumab as first-line treatment for malignant melanoma...
► Artikel lesen
19.12.23Ultimovacs - TENDU results support TET platform expansion411Ultimovacs has announced that its exploratory Phase I TENDU study, built on the company's vaccine technology platform, Tetanus-Epitope Targeting (TET), has met both its primary and secondary endpoints....
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1